Announcements Trials
Browse Landscape

Phase

Phase 1/2 7Phase 2 5Phase NA 3Phase 1 3Phase EARLY_PHASE1 1

Status

Recruiting 2Unknown 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 4OTHER_GOV 1

Study Type

Interventional 5

Sponsor

Cancer Type

CNS 5Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 276Lung Neoplasms 106Adenocarcinoma of Lung 28Mesothelioma, Malignant 22Neoplasms 19Neoplasm Metastasis 18Breast Neoplasms 13Brain Neoplasms 13Mesothelioma 10Head and Neck Neoplasms 10Ovarian Neoplasms 8Colorectal Neoplasms 8Recurrence 7Adenocarcinoma, Bronchiolo-Alveolar 7Small Cell Lung Carcinoma 6NSCLC 6Adenocarcinoma 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Meningeal Carcinomatosis 5Carcinoma 5Urinary Bladder Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Solitary Fibrous Tumor, Pleural 4Sarcoma 4Pancreatic Neoplasms 4Non-small Cell Lung Cancer Metastatic 4Laryngeal Diseases 4Carcinoma, Transitional Cell 4Uterine Neoplasms 3Uterine Cervical Neoplasms 3

Interventions

Pemetrexed 5Bevacizumab 5osimertinib 3aflutinib 3Temozolomide 3trastuzumab deruxtecan 2Topotecan 2Spinal Puncture 2Specimen Handling 2Radiotherapy, Intensity-Modulated 2Methotrexate 2Magnetic Resonance Spectroscopy 2tucatinib 1trioctyl phosphine oxide 1pembrolizumab 1nimotuzumab 1merphos 1lenvatinib 1glutathione pegylated liposomal doxorubicin 1epothilone B 1envafolimab 1camrelizumab 1XL647 1Trastuzumab 1Transplantation, Autologous 1Radiotherapy 1Radiosurgery 1Nivolumab 1Mental Status and Dementia Tests 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Meningeal Carcinomatosis × Pemetrexed × Clear all
NCT06812871 2026-04-02

High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis

Sun Yat-sen University

Phase 2 Completed
46 enrolled
CNS

Meningeal Carcinomatosis

NCT05805631 2026-03-24

Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC

Taipei Veterans General Hospital, Taiwan

Phase 2 Recruiting
23 enrolled
CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06296745 2026-01-30

Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.

Guangzhou Medical University

Phase 2 Recruiting
36 enrolled
CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06861218 2025-03-06

Cerebrospinal Fluid Cytology-guided Intrathecal Chemo-holiday Therapy for EGFR-positive NSCLC Leptomeningeal Metastases

Zhejiang Cancer Hospital

Phase 2 Not yet recruiting
42 enrolled
CNS

Meningeal Carcinomatosis

NCT05810350 2023-04-13

Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles

Three Gorges Hospital of Chongqing University

Phase 2 Unknown
40 enrolled
CNSThoracic

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡